<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40946347</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-460X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>11</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of diabetes and its complications</Title><ISOAbbreviation>J Diabetes Complications</ISOAbbreviation></Journal><ArticleTitle>Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial.</ArticleTitle><Pagination><StartPage>109175</StartPage><MedlinePgn>109175</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jdiacomp.2025.109175</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1056-8727(25)00228-4</ELocationID><Abstract><AbstractText Label="UNLABELLED">Globally, the prevalence of diabetes mellitus is rising. One of the main causes of end-stage renal disease (ESRD) and a risk factor for higher morbidity and death in diabetic patients is diabetic nephropathy (DN), sometimes referred to as diabetic kidney disease (DKD). DN, a microvascular consequence of diabetes, affects 20-40 % of diabetics globally. The study's objective was to assess if levocetirizine may have albuminuria lowering effect and anti-inflammatory effect in patients treated with angiotensin receptor blockers (ARBs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors therapy by reducing albuminuria and improving DKD indicators.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A controlled, parallel, trial was carried out on sixty DKD patients. Sixty patients were divided into two groups at random. Group 1 (control group) received an empagliflozin 10&#xa0;mg once day in addition to 80&#xa0;mg valsartan. Group 2 (levocetirizine group) received the same medications as the control group plus a 5&#xa0;mg of levocetirizine once daily in the evening, titrated dose based on each patient's creatinine clearance (CrCl) for three months. Serum creatinine, serum urea, serum cystatin-C, HbA&#x2081;c, tumor necrosis factor alpha (TNF-&#x3b1;), estimated glomerular filtration rate (eGFR), and urinary albumin to creatinine ratio (UACR) were measured at baseline and compared to these data three months after drug administration.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Levocetirizine decreased significantly UACR at the end of the three-months (p&#xa0;=&#xa0;0.037) compared to the control group. There was no variation in eGFR between the two groups, eGFR was significantly lower than baseline (p&#xa0;&lt;&#xa0;0.001) in both groups. Comparing the levocetirizine group to the control group, there is a substantial drop in TNF-&#x3b1; (p&#xa0;=&#xa0;0.004), cystatin-C (p&#xa0;=&#xa0;0.034), and HbA&#x2081;c (p&#xa0;=&#xa0;0.007).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Levocetirizine reduces albuminuria, inflammatory, and renal indicators, which makes it a potentially has albuminuria lowering effect and anti-inflammatory drug which decreases disease progression.</AbstractText><AbstractText Label="TRIAL REGISTRATION IDENTIFIER" NlmCategory="UNASSIGNED">NCT05638880.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizk</LastName><ForeName>Maryam A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Hospital Pharmacist at Ministry of Health and Population. Electronic address: amaryam10324@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Haggar</LastName><ForeName>Sahar M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Osama M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghazi</LastName><ForeName>Hossam Arafa</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Mansoura University Hospitals, Faculty of Medicine, Mansoura University, Mansoura, Al-Dakahlia, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05638880</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Diabetes Complications</MedlineTA><NlmUniqueID>9204583</NlmUniqueID><ISSNLinking>1056-8727</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Albuminuria</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Diabetic kidney disease</Keyword><Keyword MajorTopicYN="N">Levocetirizine</Keyword></KeywordList><CoiStatement>Declaration of competing interest The writers say they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>14</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>14</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>14</Day><Hour>17</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40946347</ArticleId><ArticleId IdType="doi">10.1016/j.jdiacomp.2025.109175</ArticleId><ArticleId IdType="pii">S1056-8727(25)00228-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>